Navigation Links
New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation
Date:11/14/2011

60;In the analysis, the peri-operative phase was defined as seven days before until 30 days following the procedure.(8) The analysis found no significant difference in the risk of bleeding, including major (RR = 1.08; p = 0.64), minor (RR = 1.15; p = 0.25), fatal (RR = 1.01; p = 0.99), bleeding requiring re-operation (RR = 1.39; p = 0.32) and bleeding requiring red blood cell transfusion (RR = 0.85; p = 0.37), between patients receiving PRADAXA 150mg twice daily compared to warfarin.(8)  The analysis also found that patients in all treatment arms who had emergency surgery were at much higher risk of major bleeding than those undergoing elective surgery (PRADAXA 150mg: 17.4% vs. 3.8%; warfarin: 21.7% vs. 3.3%; p<0.001 for all); however, there was no significant difference between treatment arms for either type of surgery.(8) Additionally, in all treatment arms, major bleeding was more common for major compared to minor surgery (PRADAXA 150mg: 6.4% vs. 3.2%; warfarin: 8.0% vs. 1.8%; p<0.01 for all), with no significant difference between treatment arms.(8)

About RE-LY

RE-LY was a global, Phase III, randomized trial of 18,113 patients(6) enrolled in 951 centers in 44 countries,(9) investigating whether dabigatran etexilate (two blinded doses) was as effective as well-controlled warfarin – INR 2.0 - 3.0 – (open label) for stroke prevention.(6)  Patients with non-valvular AFib and at least one other risk factor for stroke (i.e., previous ischemic stroke, transient ischemic attack, or systemic embolism, left ventricular dysfunction, age greater than or equal to 75 years, age greater than or equal to 65 years with either diabetes mellitus, history of coronary artery disease, or hypertension) were enrolled in the study for two years(6) with a minimum follow-up period of one year.(10)

The RE-LY trial utilized the established PROBE (prospective, randomized, open-label, blinded endpoint evaluation) clinical trial protoco
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Clinilabs will Conduct Phase 1 Trial Using QTinno®
3. Bright Light into the Ear Canal Treats Seasonal Depression Effectively in Two Clinical Trials Presented by Valkee and University of Oulu
4. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
5. Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer
6. NeuroCog Trials Appoints Industry Executive Michael Hufford, Ph.D. to Chief Operating Officer
7. Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer
8. Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting
9. Data From REMEDEE Trial Featuring OrbusNeichs Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
10. Conatus Pharmaceuticals Terminates Phase 2 Clinical Trial of CTS-1027
11. CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... ON , Aug. 22, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... six month periods ended June 30, 2014.  Biorem,s complete 2014 second quarter ... Financial Summary:Three-months ended June 30, , Six-months ended ... , 2014 , 2013 , 2014 ... , 4,433 , 9,195 Gross profit , 56 ...
(Date:8/22/2014)... have discovered how the receptors responsible for contractions in ... new study, published today in The FASEB Journal ... regulates the cycle of all cells in the body. ... biological clock and its control are weakened in ageing ... physiology and ageing. , While currently much ...
(Date:8/22/2014)... a study published today (August 22nd), in the ... the Champalimaud Neuroscience Programme establish the effect of ... of advanced genetic and optical techniques., "Serotonin is ... a wide range of brain functions, from the ... of complex emotional behaviours, This neurotransmitter is also ...
(Date:8/22/2014)... form and develop on platinum nanocubes point the ... and reveal that a nearly 150 year-old scientific ... nanoscale. , Researchers with the U.S. Department of ... used highly sophisticated transmission electron microscopes and an ... mechanisms that control the evolution of facets ...
Breaking Biology Technology:Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2From happiness to pain: Understanding serotonin's function 2Shaping the future of nanocrystals 2Shaping the future of nanocrystals 3Shaping the future of nanocrystals 4
... 20 /PRNewswire-FirstCall/ - Oncothyreon Inc.,(Nasdaq: ONTY ... U.S. Patent and,Trademark office has issued a ... in preclinical development. The newly issued patent, ... composition of matter of PX-867,and pharmaceutical preparations ...
... 19 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ... fully integrated,biotechnology company focused on researching, developing, ... announced today,that its board of directors has ... board has authorized 3SBio to purchase up ...
... CAMBRIDGE, Mass., March 19 Genzyme Corp.,(Nasdaq: ... application,to extend the Evoltra(R) (clofarabine) product label to include ... This,application and the data on which it was based ... by Genzyme last year., In a letter to ...
Cached Biology Technology:Oncothyreon announces issuance of patent for PX-867 2Oncothyreon announces issuance of patent for PX-867 33SBio Inc. Approves Share Repurchase Program 2Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients 2Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients 3
(Date:8/22/2014)... Reuters , a leading source of information for businesses ... of California, Riverside in its 2014 list of "some ... , To generate the list, the company analyzed citation ... published work has had enormous impact. , The following ... who published the greatest number of highly cited papers ...
(Date:8/22/2014)... CA Research presented at the 29th Annual ... developed by Hera Therapeutics Inc. combats three types ... 70 percent of all cervical cancer. , When ... blocked the replication of HPV-16, HPV-18 and HPV-11 ... Thomas Broker, Ph.D., who presented the findings at ...
(Date:8/22/2014)... French . NAIROBI ... African soils looming as a major threat to food security ... over the last five years, 1.7 million African farmers in ... million hectares and helped them double or even triple crop ... Revolution in Africa (AGRA) focuses on intensive efforts initiated five ...
Breaking Biology News(10 mins):5 UC Riverside scientists among world's most influential scientific minds 2Effort to confront Africa's soil health crisis helps millions of farmers triple yields 2Effort to confront Africa's soil health crisis helps millions of farmers triple yields 3Effort to confront Africa's soil health crisis helps millions of farmers triple yields 4
... For Immediate Release - The Scripps Research Institute has ... J. John Goodman, M.D., to Scripps Florida. The gift will ... the development of a new approach to detect and treat ... program endowment. "We are grateful to Jay and Judy ...
... Researchers have uncovered the genetic basis of remarkable broad-spectrum ... the world, is the most important pathogen affecting leafy and ... oilseed rape. They have tested resistant plants against a range ... the world and so far, no strain has been able ...
... CINCINNATIA new international population study, led by the University ... human developmental effects of environmental exposure to the complex ... UC epidemiologist Aimin Chen, MD, PhD, says research on ... in e-waste is urgently needed in order to avoid ...
Cached Biology News:New disease-resistant food crops in prospect 2Human health effects of 'e-waste' focus of international research study 2
... template DNA, primers, salts or other unwanted ... proved critical for both standard and capillary ... with dye terminator cycle sequencing chemistries such ... uniformity of the magnetic paeticles guarantees consistent ...
Human HVEM/TNFRSF14 Allophycocyanin MAb (Clone 94801)...
Mature rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and processed within 45 minutes. It is then filtered through gauze, pooled in an ...
... Freezing Point Osmometer for 10 L ... applications, including pediatric, neonatal, geriatric, general ... Automatic Calibration with 2 or 3 ... keypad and software for statistical analysis ...
Biology Products: